Login
Companies $CMPX
$0.69 +$0.03 (4.07%) After hours
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

compasstherapeutics.com

What Do They Do?

Develops antibody-based cancer drug candidates for patients with solid tumors and other cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −91% (Loss)
vs −$14.3M in Q3 FY2025
  • Apr 27, 2026 Tovecimig improved progression-free survival but missed the overall-survival endpoint Median progression-free survival was 4.7 months versus 2.6 months, while the overall-survival endpoint was not met.

A new antibody candidate The latest report adds a bispecific antibody aimed at an immune-checkpoint protein and a tumor blood-vessel growth signal, and says testing in people has begun.

Who Do They Compete With?

Competes with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck &, Novartis, Pfizer, Roche Holding, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support